Cluster-C Personality Disorders Cost €27K–€60K Per Patient Per Year — and We Keep Overlooking Them
- 375 treatment-seeking patients with Cluster-C PD across 10 Dutch outpatient sites vs 104 controls without severe mental illness — first full burden-of-disease assessment for this cluster.
- Societal cost per Cluster-C PD patient: €27,355–€60,454/year (depending on valuation method) — 2.8–4.2× higher than controls. Productivity loss, not care cost, drives most of the gap.
- Quality of life (EQ-5D-5L, MHQoL-7D) and daily functioning (WHODAS) were severely impaired — the magnitude comparable to what is already well-documented for borderline PD.
- No statistically meaningful differences in QoL, functioning, or cost between avoidant, dependent, and obsessive-compulsive PD subgroups. Cluster-C acts as a coherent burden category, not three separable ones.
Cluster-C PDs — avoidant, dependent, obsessive-compulsive — are the stepchild of personality research. BPD gets the RCTs, the MeSH headings, the DBT brand. Meanwhile the patients who show up for depression treatment and never quite get better, the ones who cancel session 4 and come back six months later with the same presenting problem, disproportionately carry Cluster-C features. This study is the first to put concrete economic weight behind that clinical impression.
Where the cost actually lives
The headline numbers are large: €27K–€60K per patient per year, 2.8–4.2× controls. What matters is the decomposition. Direct treatment cost is a minority share. The bulk comes from productivity loss — sick leave, reduced work hours, presenteeism, early exit from the labour force. Avoidant and dependent patients in particular accumulate functional impairment slowly, so it is rarely framed as a crisis and rarely prioritised in treatment planning. The Netherlands sample is instructive because the country has relatively good mental-health access — these costs occur despite treatment being available, not because it is absent.
For your practice
Three clinical shifts follow. First, when you assess a depressed or anxious patient with a chronic course and partial treatment response, the differential now has quantified consequences — screening for Cluster-C features (SCID-5-PD, IPDE-SQ) is no longer optional diligence, it is economically justified. Second, the non-significant differences between avoidant, dependent, and OCPD subgroups support treating Cluster-C as a single target domain for intervention — schema therapy, MIT, and contextual schema therapy all already do this implicitly. Third, if you advocate for insurance coverage or employer-provided MH benefits, this is the citation that links Cluster-C treatment to labour-force outcomes.
Cluster-C personality disorders cost €27K–€60K per patient per year and still do not get a fraction of the research attention we give BPD.
Dutch healthcare context limits direct generalisation. Cost-interview is self-report and retrospective. No longitudinal data on whether treatment reduces these costs.